Profil
Raimund Strehl is currently the Chief Technology Officer at NovaHep AB.
Previously, he held the same position at Takara Bio Europe AB.
Postes actifs de Raimund Strehl
| Sociétés | Poste | Début |
|---|---|---|
NovaHep AB
 NovaHep AB Miscellaneous Commercial ServicesCommercial Services NovaHep AB provides stem-cell research for gene therapy of liver diseases. Its main area of focus is the development of biological, individualised blood vessels that can be used to replace non-functioning blood vessels in patients with different types of vascular disease. The company was founded by Suchitra Sumitran-Holgersson and Jan Anders Holgersson in 2005 and is headquartered in Gothenburg, Sweden. | Directeur Technique/Scientifique/R&D | - |
Anciens postes connus de Raimund Strehl
| Sociétés | Poste | Fin |
|---|---|---|
Takara Bio Europe AB
 Takara Bio Europe AB Miscellaneous Commercial ServicesCommercial Services Takara Bio Europe AB is a provider of stem cell derived products and technologies which will drive unprecedented innovation in drug discovery and regenerative medicine today and in the future. The company was first in the world to bring to the market human embryonic stem (hES) cell-derived hepatocytes and cardiomyocytes for use as drug discovery tools. Cellartis is also the single commercial source of ethically derived hES cell lines and has developed cell lines for a range of uses. This hES cell technology platform offers a path to tools and regenerative medicine discoveries of the future. The company was founded in 2001 and is headquartered in Gothenburg, Sweden. | Directeur Technique/Scientifique/R&D | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
Takara Bio Europe AB
Takara Bio Europe AB Miscellaneous Commercial ServicesCommercial Services Takara Bio Europe AB is a provider of stem cell derived products and technologies which will drive unprecedented innovation in drug discovery and regenerative medicine today and in the future. The company was first in the world to bring to the market human embryonic stem (hES) cell-derived hepatocytes and cardiomyocytes for use as drug discovery tools. Cellartis is also the single commercial source of ethically derived hES cell lines and has developed cell lines for a range of uses. This hES cell technology platform offers a path to tools and regenerative medicine discoveries of the future. The company was founded in 2001 and is headquartered in Gothenburg, Sweden. | Commercial Services |
NovaHep AB
NovaHep AB Miscellaneous Commercial ServicesCommercial Services NovaHep AB provides stem-cell research for gene therapy of liver diseases. Its main area of focus is the development of biological, individualised blood vessels that can be used to replace non-functioning blood vessels in patients with different types of vascular disease. The company was founded by Suchitra Sumitran-Holgersson and Jan Anders Holgersson in 2005 and is headquartered in Gothenburg, Sweden. | Commercial Services |
